Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Omeprazole on Tipranavir/Ritonavir PK in Healthy Volunteers
NCT02253875Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum plasma concentration of Tipranavir up to 72 hours and Area Under Plasma Concentration-time curve of Tipranavir from 0-72 hr. Started Nov 2005; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02253875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253875.